Skip to main content

Advertisement

SpringerLink
Log in

Cryptococcal Immune Reconstitution Inflammatory Syndrome: a Paradoxical Response to a Complex Organism

  • Fungal Infections (O De la Cruz and F Silveira, Section Editors)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Abstract

Purpose of review

To describe the host-pathogen factors that impact the management of cryptococcal meningitis (CM) in immunosuppressed patients that lead to the development of cryptococcal immune reconstitution inflammatory syndrome (C-IRIS).

Recent findings

The pre-screening of HIV-infected patients in resource-poor countries with the lateral flow cryptococcal antigen assay could prevent C-IRIS. Delaying ART by 4 weeks is associated with improved survival and recommended by guidelines; this approach remains controversial in wealthier areas as there is limited data. A 5-flucytosine-based combination regimen and avoidance of corticosteroids on initial treatment improve cryptococcus clearance from cerebrospinal fluid. New monoclonal antibodies and kinase inhibitors that alter the immune system, such as ibrutinib and ruxolitinib, have been associated with cryptococcosis.

Summary

It is important to recognize that restoration of the immune system, regardless of the host, can lead to C-IRIS. Prevention of C-IRIS by pre-screening patients, delaying antiretroviral therapy, and using a 5-flucytosine backbone regimen are important in the management of meningitis. C-IRIS management requires the exclusion of therapeutic failure or antifungal resistance. Further research is needed on whether delaying antiretroviral therapy by 4 weeks is necessary in wealthier countries to improve C-IRIS outcomes, and whether C-IRIS can be seen with new immunologic agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genet Biol. 2015;78:49–54. https://doi.org/10.1016/j.fgb.2014.10.003Excellent paper on diagnosis and management of cryptococcal infections.

  2. •Kwon-Chung KJ, Bennett JE, Wickes BL, Meyer W, Cuomo CA, Wollenburg KR, et al. The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis. mSphere. 2017;2:1. https://doi.org/10.1128/mSphere.00357-16This paper describes the reasons for renaming all the cryptococcal species that infect humans.

    Article  Google Scholar 

  3. Day JN, Qihui S, Thanh LT, Trieu PH, Van AD, Thu NH, et al. Comparative genomics of Cryptococcus neoformans var. grubii associated with meningitis in HIV infected and uninfected patients in Vietnam. PLoS Negl Trop Dis. 2017:e0005628. https://doi.org/10.1371/journal.pntd.0005628.

  4. Desjardins CA, Giamberardino C, Sykes SM, Yu CH, Tenor JL, Chen Y, et al. Population genomics and the evolution of virulence in the fungal pathogen Cryptococcus neoformans. Genome Res. 2017;27:1207–19. https://doi.org/10.1101/gr.218727.116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Knoke M, Schwesinger G. One hundred years ago: the history of cryptococcosis in Greifswald. Medical mycology in the nineteenth century. Mycoses. 1994;37:229–33. https://doi.org/10.1111/j.1439-0507.1994.tb00418x.

    Article  CAS  PubMed  Google Scholar 

  6. Emmons CW. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am J Hyg. 1955;62:227–32. https://doi.org/10.1093/oxfordjournals.aje.a119775.

    Article  CAS  PubMed  Google Scholar 

  7. Ruiz A, Neilson JB, Bulmer GS. Control of Cryptococcus neoformans in nature by biotic factors. Sabouraudia. 1982;20:21–9.

    Article  CAS  Google Scholar 

  8. Steenbergen JN, Shuman HA, Casadevall A. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A. 2001;26:15245–50. https://doi.org/10.1073/pnas.261418798.

    Article  CAS  Google Scholar 

  9. Chen SC, Meyer W, Sorrell TC. Cryptococcus gattii infections. Clin Microbiol Rev. 2014;27:980–1024. https://doi.org/10.1128/CMR.00126-13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Datta K, Bartlett KH, Baer R, Byrnes E, Galanis E, Heitman J, et al. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg Infect Dis. 2009;15:1185–91. https://doi.org/10.3201/eid1508.081384.

    Article  PubMed  PubMed Central  Google Scholar 

  11. •Harris JR, Lockhart SR, Debess E, Marsden-Haug N, Goldoft M, Wohrle R, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis. 2011;53:1188–95. https://doi.org/10.1093/cid/cir723Important description of Cryptococcal gattii infections in the Northwestern US states.

  12. Phillips P, Galanis E, MacDougall L, Chong MY, Balshaw R, Cook VJ, et al. Longitudinal clinical findings and outcome among patients with Cryptococcus gattii infection in British Columbia. Clin Infect Dis. 2015;60:1368–76. https://doi.org/10.1093/cid/civ041.

    Article  PubMed  Google Scholar 

  13. Forrest GN, Bhalla P, DeBess EE, Winthrop KL, Lockhart SR, Mohammadi J, et al. Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases. Transpl Infect Dis. 2015;17:467–76. https://doi.org/10.1111/tid.12370.

    Article  CAS  PubMed  Google Scholar 

  14. Perfect JR, Casadevall A. Cryptococcosis. Infect Dis Clin N Am. 2003;16:837–74. https://doi.org/10.1016/s0891-5520(02)00036-3.

    Article  Google Scholar 

  15. •Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17:873–81. https://doi.org/10.1016/S1473-3099(17)30243-8This article provides excellent data on the current burden of cryptococcocal meningits and information on patient populations most at risk.

  16. Williamson PR. The relentless march of cryptococcal meningitis. Lancet Infect Dis. 2017;13:790–1. https://doi.org/10.1038/nrneurol.2016.167.

    Article  CAS  Google Scholar 

  17. Haugen RK, Baker RD. The pulmonary lesions in cryptococcosis with special reference to subpleural nodules. Am J Clin Pathol. 1954;24:1381–90. https://doi.org/10.1093/ajcp/24.12.1381.

    Article  CAS  PubMed  Google Scholar 

  18. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol. 1999;37:3204–9.

    Article  CAS  Google Scholar 

  19. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100. https://doi.org/10.1086/651263.

    Article  PubMed  Google Scholar 

  20. Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis. 2009;48:1566–76. https://doi.org/10.1086/598936.

    Article  PubMed  Google Scholar 

  21. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 2001;7:375–81. https://doi.org/10.3201/eid0703.010302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis. 2007;195:756–64. https://doi.org/10.1086/511438.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Singh N, Husain S, De Vera M, Gayowski T, Cacciarelli TV. Cryptococcus neoformans Infection in Patients With Cirrhosis, Including Liver Transplant Candidates. Medicine (Baltimore). 2004;83:188–92. https://doi.org/10.1097/01.md.0000126760.45299.69.

    Article  Google Scholar 

  24. Singh N, Huprikar S, Burdette SD, Morris MI, Blair JE, Wheat LJ. Donor-Derived Fungal Infections in Organ Transplant Recipients: Guidelines of the American Society of Transplantation, Infectious Diseases Community of Practice(dagger). Am J Transplant. 2012;12:2414–28. https://doi.org/10.1111/j.1600-6143.2012.04100.x.

    Article  CAS  PubMed  Google Scholar 

  25. Lionakis MS, Netea MG, Holland SM. Mendelian genetics of human susceptibility to fungal infection. Cold Spring Harb Perspect Med. 2014;4:6. https://doi.org/10.1101/cshperspect.a019638.

    Article  CAS  Google Scholar 

  26. ••Gundacker NDB, JW. Fungal Infections in the Era of Biologic Therapies. Curr Clin Micro Rpt. 2015;2:76–83. https://doi.org/10.1007/s40588-015-0018-yThis article provides an important review of the role of new TNF-alpha inhibitors in the role of invasive fungal infections.

  27. Nielsen K, Cox GM, Litvintseva AP, Mylonakis E, Malliaris SD, Benjamin DK Jr, et al. Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun. 2005;73:4922–33. https://doi.org/10.1128/IAI.73.8.4922-4933.2005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Perfect JR. Cryptococcus neoformans: a sugar-coated killer with designer genes. FEMS Immunol Med Microbiol. 2005;45:395–404. https://doi.org/10.1016/j.femsim.2005.06.005.

    Article  CAS  PubMed  Google Scholar 

  29. Bratton EW, El Husseini N, Chastain CA, Lee MS, Poole C, Sturmer T, et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One. 2012;7:e43582. https://doi.org/10.1371/journal.pone.0043582.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Santangelo R, Zoellner H, Sorrell T, Wilson C, Donald C, Djordjevic J, et al. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect Immun. 2004;72:2229–39. https://doi.org/10.1128/iai.72.4.2229-2239.2004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Casadevall A. Cryptococci at the brain gate: break and enter or use a Trojan horse? J Clin Invest. 2010;120:1389–92. https://doi.org/10.1172/JCI42949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Jarvis JN, Meintjes G, Bicanic T, Buffa V, Hogan L, Mo S, et al. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. PLoS Pathog. 2015;11:e1004754. https://doi.org/10.1371/journal.ppat.1004754.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Haidar G, Singh N. Cryptococcus: Shedding New Light on an Inveterate Yeast. J Fungi (Basel). 2015;1:115–29. https://doi.org/10.3390/jof1020115.

    Article  Google Scholar 

  34. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 2010;21:e1000384. https://doi.org/10.1371/journal.pmed.1000384.

    Article  Google Scholar 

  35. •Oshima K, Takazono T, Saijo T, Tashiro M, Kurihara S, Yamamoto K, et al. Examination of cryptococcal glucuronoxylomannan antigen in bronchoalveolar lavage fluid for diagnosing pulmonary cryptococcosis in HIV-negative patients. Med Mycol. 2018;56:88–94. https://doi.org/10.1093/mmy/myx010This article examines the performance of the cryptococcal glucuronoxylomannan (GXM)antigen test from bronchoalveolar lavage fluid (BALF) samples, in an HIV-negative patients. The article suggests the BALF GXM may have a role in the early diagnosis of pulmonary cryptococcosis.

  36. Buchanan KL, Murphy JW. What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis. 1998;4:71–83. https://doi.org/10.3201/eid0401.980109.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis. 2007;7:395–401. https://doi.org/10.1016/s1473-3099(07)70085-3.

    Article  PubMed  Google Scholar 

  38. Einsiedel L, Gordon DL, Dyer JR. Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman. Clin Infect Dis. 2004;39:e78–82. https://doi.org/10.1086/424746.

    Article  PubMed  Google Scholar 

  39. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291–322. https://doi.org/10.1086/649858.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Vidal JE, Boulware DR. Lateral Flow Assay for Cryptococcal Antigen: An Important Advance to Improve the Continuum of Hiv Care and Reduce Cryptococcal Meningitis-Related Mortality. Rev Inst Med Trop Sao Paulo. 2015;15(Suppl19):38–45. https://doi.org/10.1590/S0036-46652015000700008.

    Article  Google Scholar 

  41. Vijayan T, Chiller T, Klausner JD. Sensitivity and specificity of a new cryptococcal antigen lateral flow assay in serum and cerebrospinal fluid. MLO Med Lab Obs. 2013;45:16 18, 20.

    PubMed  PubMed Central  Google Scholar 

  42. Kabanda T, Siedner MJ, Klausner JD, Muzoora C, Boulware DR. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis. 2014;58:113–6. https://doi.org/10.1093/cid/cit641.

    Article  CAS  PubMed  Google Scholar 

  43. O'Connor L, Livermore J, Sharp AD, Goodwin J, Gregson L, Howard SJ, et al. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. J Infect Dis. 2013;208:351–61. https://doi.org/10.1093/infdis/jit164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. •Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368:1291–302. https://doi.org/10.1056/NEJMoa1110404Important randomized study that showed 5 flucytosine combination therapy reduced mortality and imprved cerebrospinal fluid clearance. Also, fluconazole monotherapy as initial therapy resulted in delayed clearance and increased mortality.

  45. Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, et al. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. Trials. 2018;19:649. https://doi.org/10.1186/s13063-018-3026-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. ••Jarvis JN, Leeme TB, Molefi M, Chofle AA, Bidwell G, Tsholo K, et al. Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. Clin Infect Dis. 2019;68:393–401. https://doi.org/10.1093/cid/ciy515Early treatment paper with weekly amphotericin B, but importantly daily 5 flucytosine showing early clearance and similar outcomes. Outcomes still better than non 5 flucytosine therapies.

  47. Longley N, Harrison TS, Jarvis JN. Cryptococcal immune reconstitution inflammatory syndrome. Curr Opin Infect Dis. 2013;26:26–34. https://doi.org/10.1097/QCO.0b013e32835c21d1.

    Article  CAS  PubMed  Google Scholar 

  48. Rolfes MA, Hullsiek KH, Rhein J, Nabeta HW, Taseera K, Schutz C, et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis. 2014;59:1607–14. https://doi.org/10.1093/cid/ciu596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. ••Beardsley J, Wolbers M, Kibengo FM, Ggayi AB, Kamali A, Cuc NT, et al. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med. 2016;374:542–54. https://doi.org/10.1056/NEJMoa1509024Critically important paper showing that early dexamethasone therapy resulted in dleayed cryptococcal clearance and increased mortality.

  50. ••Beardsley J, Hoang NLT, Kibengo FM, Tung NLN, Binh TQ, Hung LQ, et al. Do Intracerebral Cytokine Responses Explain the Harmful Effects of Dexamethasone in Human Immunodeficiency Virus-associated Cryptococcal Meningitis? Clin Infect Dis. 2019;68:1494–501. https://doi.org/10.1093/cid/ciy725Another paper showing how dexamethasone delays clearance of cryptococcus through Interleukin-10.

  51. Shelburne SA 3rd, Darcourt J, White AC Jr, Greenberg SB, Hamill RJ, Atmar RL, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005, 40:1049–52. https://doi.org/10.1086/428618.

  52. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005;19:1043–9. https://doi.org/10.1097/01.aids.000174450.70874.30.

    Article  PubMed  Google Scholar 

  53. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19:399–406. https://doi.org/10.1097/01aids.000161769.06158.8a.

    Article  PubMed  Google Scholar 

  54. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS. 2008;22:601–10. https://doi.org/10.1097/QAD.0b013e3282f4a607.

    Article  CAS  PubMed  Google Scholar 

  55. Michelet C, Arvieux C, Francois C, Besnier JM, Rogez JP, Breux JP, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS. 1998;12:1815–22. https://doi.org/10.1097/00002030-199814000-00013.

    Article  CAS  PubMed  Google Scholar 

  56. Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10:791–802. https://doi.org/10.1016/S1473-3099(10)70170-5.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, Kambugu A, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis. 2010;202:962–70. https://doi.org/10.1086/655785.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516–23. https://doi.org/10.1016/S1473-3099(08)70184-1.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, Hogg R, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis. 2005;41:1483–97. https://doi.org/10.1086/497269.

    Article  PubMed  Google Scholar 

  60. Manfredi R, Pieri F, Pileri SA, Chiodo F. The changing face of AIDS-related opportunism: cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review. Mycopathologia. 1999;148:73–8. https://doi.org/10.1023/a:1007156027134.

    Article  CAS  PubMed  Google Scholar 

  61. Boelaert JR, Goddeeris KH, Vanopdenbosch LJ, Casselman JW. Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. AIDS. 2004;18:1223–4. https://doi.org/10.1097/00002030-200405210-00023.

    Article  PubMed  Google Scholar 

  62. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS. 2005;19:2050–2. https://doi.org/10.1097/01.aids.0000191232.16111.f9.

    Article  PubMed  Google Scholar 

  63. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;37:2487–98. https://doi.org/10.1056/NEJMoa1312884.

    Article  CAS  Google Scholar 

  64. ••Eshun-Wilson I, Okwen MP, Richardson M, Bicanic T. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7:CD009012. https://doi.org/10.1002/14651858.CD009012.pub3This is a review of 4 studies in patients with cryptococcal meningitis from low and middle-income countries. It outlines the relative risk for development of C-IRIS when starting ART early vs. delayed initiation of ART (>4 weeks). It provides the basis for concern for too early an initiation of ART in the setting of cryptococcal meningitis in low income countries.

    Article  PubMed  Google Scholar 

  65. ••Delliere S, Guery R, Candon S, Rammaert B, Aguilar C, Lanternier F, et al. Understanding Pathogenesis and Care Challenges of Immune Reconstitution Inflammatory Syndrome in Fungal Infections. J Fungi (Basel). 2018;4:E139. https://doi.org/10.3390/jof4040139This is an excellent review of the pathophysiology of C-IRIS and the role of various cytokines as well as the role the predominant T-Helper cells play in both disease control and C-IRIS.

  66. Martin-Blondel G, Mars LT, Liblau RS. Pathogenesis of the immune reconstitution inflammatory syndrome in HIV-infected patients. Curr Opin Infect Dis. 2012;25:312–20. https://doi.org/10.1097/QCO.0b013e328352b664.

    Article  CAS  PubMed  Google Scholar 

  67. Bellocchio S, Gaziano R, Bozza S, Rossi G, Montagnoli C, Perruccio K, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. The Journal of Antimicrob Chemother. 2005;55:214–22. https://doi.org/10.1093/jac/dkh542.

    Article  CAS  Google Scholar 

  68. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis. 2008;47:226–35. https://doi.org/10.1086/589290.

    Article  CAS  PubMed  Google Scholar 

  69. Meya DB, Okurut S, Zziwa G, Cose S, Boulware DR, Janoff EN. HIV-Associated Cryptococcal Immune Reconstitution Inflammatory Syndrome Is Associated with Aberrant T Cell Function and Increased Cytokine Responses. J Fungi (Basel). 2019;5:E42. https://doi.org/10.3390/jof5020042.

    Article  CAS  Google Scholar 

  70. ••Rajasingham R, Wake RM, Beyene T, Katende A, Letang E, Boulware DR. Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. J Clin Microbiol. 2018;57:e01238–18. https://doi.org/10.1128/JCM.01238-18Important paper on the lateral flow assay and pre-screening HIV-infected patients for cryptococcal infection prior to starting antiretrovial therapy to minimize IRIS.

  71. Singh N, Lortholary O, Alexander BD, Gupta KL, John GT, Pursell K, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis. 2005;40:1756–61. https://doi.org/10.1086/430606.

    Article  CAS  PubMed  Google Scholar 

  72. Lanternier F, Chandesris MO, Poiree S, Bougnoux ME, Mechai F, Mamzer-Bruneel MF, et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant. 2007;7:2826–8. https://doi.org/10.1111/j.1600-6143.2007.01994x.

    Article  CAS  PubMed  Google Scholar 

  73. •Sun HY, Alexander BD, Huprikar S, Forrest GN, Bruno D, Lyon GM, et al. Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression. Clin Infect Dis. 2015;60:36–44. https://doi.org/10.1093/cid/ciu711This is an important case series looking at variables that pose a risk for development of C-IRIS in Solid Organ Transplant recipients.

  74. Singh N, Lortholary O, Alexander BD, Gupta KL, John GT, Pursell K, et al. Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. Transplantation. 2005;80:1131–3. https://doi.org/10.1097/01.tp.0000180530.17683.02.

    Article  PubMed  Google Scholar 

  75. D'Elios MM, Josien R, Manghetti M, Amedei A, de CM, Cuturi MC, et al. Predominant Th1 cell infiltration in acute rejection episodes of human kidney grafts. Kidney Int. 1997;51:1876–84. https://doi.org/10.1038/ki.1997.256.

    Article  CAS  PubMed  Google Scholar 

  76. Wiesner DL, Boulware DR. Cryptococcus-Related Immune Reconstitution Inflammatory Syndrome(IRIS): Pathogenesis and Its Clinical Implications. Curr Fungal Infect Rep. 2011;5:252–61. https://doi.org/10.1007/s12281-011-0064-8.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Ingram PR, Howman R, Leahy MF, Dyer JR. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis. 2007;44:e115–e7. https://doi.org/10.1086/518168.

    Article  PubMed  Google Scholar 

  78. •Liao TL, Chen YM, Chen DY. Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications. Clin Microbiol Infect. 2016;22:815 e1–3. https://doi.org/10.1016/j.cmi.2016.05.030This is a review of the role immunomodulatory agents, in particular monoclonal anti-tumour necrosis factor (TNF) antibodies, may play in increasing risk of cryptococcosis.

    Article  Google Scholar 

  79. Hage CA, Wood KL, Winer-Muram HT, Wilson SJ, Sarosi G, Knox KS. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest. 2003;124:2395–7. https://doi.org/10.1378/chest.124.6.2395.

    Article  PubMed  Google Scholar 

  80. Marchand T, Revest M, Tattevin P, Chevrier S, Poullot E, Lamy T, et al. Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:643–5. https://doi.org/10.3109/10428194.2012.717081.

    Article  CAS  PubMed  Google Scholar 

  81. Ettahar N, Legout L, Ajana F, Patoz P, Massongo M, Rose C, et al. Cryptococcal osteomyelitis in a patient with a lymphocytic leukemia treated with fludarabine-cyclophosphamide-rituximab. J Mycol Med. 2013;23:57–63. https://doi.org/10.1016/j.mycmed.2012.12.049.

    Article  CAS  PubMed  Google Scholar 

  82. Wingfield T, Jani M, Krutikov M, Mayer J, Uriel A, Marks J, et al. Cryptococcal meningitis in an HIV-negative patient with rheumatoid arthritis treated with rituximab. Rheumatology (Oxford). 2011;50:1725–7. https://doi.org/10.1093/rheumatology/ker210.

    Article  CAS  Google Scholar 

  83. Sanchez-Ojanguren J, Isern-Segura I, Chico-Chumillas C, Javaloyas-de-Morlius M. Cryptococcus neoformans meningoencephalitis in a patient treated with rituximab. Med Clin (Barc). 2009;133:157–8. https://doi.org/10.1016/j.medcli.2008.09.036.

    Article  Google Scholar 

  84. Okamoto K, Proia LA, Demarais PL. Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib. Case Rep Infect Dis. 2016;2016:4642831. https://doi.org/10.1155/2016/4642831.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Messina JA, Maziarz EK, Spec A, Kontoyiannis DP, Perfect JR. Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. Open Forum Infect Dis. 2017;4:ofw261. https://doi.org/10.1093/ofid/ofw261.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Abid MB, Stromich J, Gundacker ND. Is ibrutinib associated with disseminated cryptococcosis with CNS involvement? Cancer Biol Ther. 2018;20:1–3. https://doi.org/10.1080/15384047.2018.1508622.

    Article  CAS  Google Scholar 

  87. ••Chamilos G, Lionakis MS, Kontoyiannis DP. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clin Infect Dis. 2018;66:140–8. https://doi.org/10.1093/cid/cix687Excellent review the role on ibrutinib and other small molecule kinase inhibitors may play in increasing the risk of cryptococcosis and other invasive fungal infections. A neglected area of knowledge expanded by this paper.

  88. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143:1478–9. https://doi.org/10.1378/chest.12-1604.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Prakash K, Richman D. A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib. BMC Infect Dis. 2019;19:287. https://doi.org/10.1186/s12879-019-3922-6.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Liu J, Mouhayar E, Tarrand JJ, Kontoyiannis DP. Fulminant Cryptococcus neoformans infection with fatal pericardial tamponade in a patient with chronic myelomonocytic leukaemia who was treated with ruxolitinib: Case report and review of fungal pericarditis. Mycoses. 2018;61:245–55. https://doi.org/10.1111/myc.12735.

    Article  PubMed  Google Scholar 

  91. Hirano A, Yamasaki M, Saito N, Iwato K, Daido W, Funaishi K, et al. Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis. Respir Med Case Rep. 2017;22:87–90. https://doi.org/10.1016/j.rmcr.2017.06.015.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Chen CC, Chen YY, Huang CE. Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib. Ann Hematol. 2016;95:361–2. https://doi.org/10.1007/s00277-015-2532-7.

    Article  PubMed  Google Scholar 

  93. •Dioverti MV, Abu Saleh OM, Tande AJ. Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature. Infect Dis (Lond). 2018:50, 381–357. https://doi.org/10.1080/23744235.2017.1390248This is an excellent review on the role of Ruxolitinib, a Janus kinase 2 inhibitor in increasing the risk of invasive fungal infections.

  94. Reinwald M, Boch T, Hofmann WK, Buchheidt D. Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomark Insights. 2016;10(Suppl 3):55–68. https://doi.org/10.4137/BMI.S22430.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin N Am. 2016;30:179–206. https://doi.org/10.1016/j.idc.2015.10.006.

    Article  Google Scholar 

  96. Graybill JR, Sobel J, Saag M, Van der HC, Powderly W, Cloud G, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30:47–54. https://doi.org/10.1086/313603.

    Article  CAS  PubMed  Google Scholar 

  97. Sitapati AM, Kao CL, Cachay ER, Masoumi H, Wallis RS, Mathews WC. Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab. Clin Infect Dis. 2010;50:e7–10. https://doi.org/10.1086/649553.

Download references

Author information

Authors and Affiliations

  1. Providence St. Vincent Medical Center, Portland, OR, USA

    Imran Mohamedy M.B.B.S.

  2. VA Portland Healthcare System, Oregon Health and Science University, Portland, OR, USA

    Graeme N. Forrest M.B.B.S.

Authors
  1. Imran Mohamedy M.B.B.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Graeme N. Forrest M.B.B.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Imran Mohamedy M.B.B.S..

Ethics declarations

Conflict of interest

Imran Mohamedy declares that he has no conflict of interest.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Fungal Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohamedy, I., Forrest, G.N. Cryptococcal Immune Reconstitution Inflammatory Syndrome: a Paradoxical Response to a Complex Organism. Curr Treat Options Infect Dis 12, 13–29 (2020). https://doi.org/10.1007/s40506-020-00210-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-020-00210-z

Keywords

Search

Navigation